Get Even More Visitors To Your Blog, Upgrade To A Business Listing >>

EXACT Sciences (NDAQ:EXAS) Investors: Lake Street Reconfirms Hold Rating, Sees $41.00/Share

NewYork EXACT Sciences NDAQ:EXAS

EXACT Sciences (NDAQ:EXAS) Rating Restated

EXACT Sciences (NDAQ:EXAS) had its stock rating noted as Hold by analysts at Lake Street. Lake Street currently has a $41.00 TP on the $4.44B market cap company or 2.63 % upside potential. This was revealed to investors in a report on 26 July.

NDAQ:EXAS is right now trading 6.21% higher at $39.65 as of 8:01 AM New York time. EXACT Sciences’s stock is 0% over the last 200 days. It has underperformed the Standard & Poor’s 500 index, which has added 6.00% over the same time period.

Out of 10 brokers covering EXACT Sciences, 6 rate it a Buy, 7 indicate a Hold while 0 suggest a Sell. The highest target is $13 and the lowest is $6 according to Thomson/First Call. The 12-month mean target is $8.55, which means downside potential of 78.44% over the current price.

EXAS Stock Chart

Institutional Ownership

Antipodean Advisors Llc had the most significant stake with ownership of 751,946 shares as of q2 2015 for 6.91% of the long stock exposure. J&P(China)Capital Management Co.Ltd is another bull as the institutional investor who is having 1.25M shares of EXACT Sciences or 6.33% of their long stock exposure. Moreover, Thompson Investment Management Inc. have 2.22% of their long stock exposure invested in the company for 621,074 shares. The Washington-based fund Zevenbergen Capital Investments Llc revealed it had acquired a stake worth about 1.83% of the institutional investor’s stock portfolio in EXACT Sciences. The Wisconsin-based fund Broadview Advisors Llc is also positive about the stock, possessing 2.40M shares or 1.52% of their long stock exposure.

EXACT Sciences (NDAQ:EXAS) Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer.

EXACT Sciences (NDAQ:EXAS) traded up 6.21% on 26 July, hitting $39.65. A total of 7.79 million shares of the company’s stock traded hands. This is up from average of 2.10 million shares. EXACT Sciences has a 52 week low of $13.05 and a 52 week high of $42.18. The company has a market cap of $4.44 billion and a P/E ratio of 0.

Get the latest EXACT Sciences (NDAQ:EXAS) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.

The post EXACT Sciences (NDAQ:EXAS) Investors: Lake Street Reconfirms Hold Rating, Sees $41.00/Share appeared first on Octafinance.

This post first appeared on Octafinance – Financial News, Reports And Intell, please read the originial post: here

Share the post

EXACT Sciences (NDAQ:EXAS) Investors: Lake Street Reconfirms Hold Rating, Sees $41.00/Share


Subscribe to Octafinance – Financial News, Reports And Intell

Get updates delivered right to your inbox!

Thank you for your subscription